172 related articles for article (PubMed ID: 10840069)
1. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Papamichael D
Stem Cells; 2000; 18(3):166-75. PubMed ID: 10840069
[TBL] [Abstract][Full Text] [Related]
2. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Papamichael D
Oncologist; 1999; 4(6):478-87. PubMed ID: 10631692
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase: a critical target for cancer chemotherapy.
Rose MG; Farrell MP; Schmitz JC
Clin Colorectal Cancer; 2002 Feb; 1(4):220-9. PubMed ID: 12450420
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of colorectal cancer: history and new themes.
Bertino JR
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-3-S18-7. PubMed ID: 9420015
[TBL] [Abstract][Full Text] [Related]
5. New systemic frontline treatment for metastatic colorectal carcinoma.
Braun AH; Achterrath W; Wilke H; Vanhoefer U; Harstrick A; Preusser P
Cancer; 2004 Apr; 100(8):1558-77. PubMed ID: 15073842
[TBL] [Abstract][Full Text] [Related]
6. Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer.
Clark JW
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-19-S18-24. PubMed ID: 9420017
[TBL] [Abstract][Full Text] [Related]
7. [Recent advance in chemotherapy for advanced colorectal cancer].
Aiba K
Gan To Kagaku Ryoho; 1996 Apr; 23(5):535-48. PubMed ID: 8678510
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
9. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
Ford HE; Mitchell F; Cunningham D; Farrugia DC; Hill ME; Rees C; Calvert AH; Judson IR; Jackman AL
Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
[TBL] [Abstract][Full Text] [Related]
10. New drugs in therapy of colorectal cancer: preclinical studies.
Rustum YM; Cao S
Semin Oncol; 1999 Dec; 26(6):612-20. PubMed ID: 10606254
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of two fluorouracil administration regimens for colorectal cancer.
Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
[TBL] [Abstract][Full Text] [Related]
13. The treatment of advanced colorectal cancer: where are we now and where do we go?
Van Cutsem E; Verslype C; Demedts I
Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):319-30. PubMed ID: 11969241
[TBL] [Abstract][Full Text] [Related]
14. The medical treatment of colorectal cancer: actual status and new developments.
Van Cutsem E; Peeters M; Verslype C; Filez L; Haustermans K; Janssens J
Hepatogastroenterology; 1999; 46(26):709-16. PubMed ID: 10370599
[TBL] [Abstract][Full Text] [Related]
15. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
16. New concepts for the development and use of antifolates.
Chu E; Grem JL; Johnston PG; Allegra CJ
Stem Cells; 1996 Jan; 14(1):41-6. PubMed ID: 8820950
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
18. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
19. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
Etienne-Grimaldi MC; Cardot JM; François E; Renée N; Douillard JY; Gamelin E; Milano G
Clin Pharmacol Ther; 2008 Mar; 83(3):413-5. PubMed ID: 17637782
[TBL] [Abstract][Full Text] [Related]
20. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]